Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

Change is exciting, and it comes with risks. This is why turnaround stocks are so interesting. Right now, Teva Pharmaceutical Industries (NYSE: TEVA) is a turnaround story that may appeal to investors. But if you like dividends, you'll probably prefer this drug competitor and its lofty 6.3% yield. Here's why.Teva doesn't currently pay a dividend, so it is hard for it to compete with any company that does if income is a key investment goal. That said, the S&P 500 index has a 1.1% yield today. The average pharmaceutical stock yields around 1.7%. And then there are drug giants like Pfizer (NYSE: PFE), which has a yield of 6.3%. But a high yield alone isn't enough to make a stock worth buying.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool